

## Results of 2024 Annual General Meeting

---

**Melbourne, Australia** – Tryptamine Therapeutics Limited (“**Tryp**” or the “**Company**”) (**ASX: TYP**), a clinical-stage biotechnology company, announces that at today’s Annual General Meeting shareholders of the Company by way of poll:

1. passed all Resolutions, except for Resolutions 5 and 14;
2. did not pass Resolutions 5 and 14; and
3. In respect to Resolution 1 "Adoption of Remuneration Report", the resolution passed with in excess of 75% votes in favour of the resolution.

In accordance with ASX Listing Rule 3.13.2 and Section 251AA(2) of the Corporations Act 2001 (Cth), a summary of the proxy votes and the number of votes cast on each resolution in the poll is attached.

—ENDS—

*This announcement was authorised for issue by the Company Secretary, Mr David Franks, on behalf of the Board.*

### **About Tryptamine Therapeutics Limited**

Tryp Therapeutics is a clinical-stage biotechnology company focused on developing proprietary, novel formulations for the administration of psilocin in combination with psychotherapy to treat diseases with unmet medical needs. Tryp’s lead program, TRP-8803, is a proprietary formulation of IV-infused psilocin (the active metabolite of psilocybin) with potential to alleviate numerous shortcomings of oral psilocybin including: significantly reducing the time to onset of the psychedelic state, controlling the depth and duration of the psychedelic experience, and reducing the overall duration of the intervention to a commercially feasible timeframe. The Company has completed a Phase 2a clinical trial for the treatment of binge eating disorder at the University of Florida, which demonstrated an average reduction in binge eating episodes of greater than 80%.

The Company also has also just completed a Phase 2a clinical trial for the treatment of fibromyalgia in collaboration with the University of Michigan and has initiated a Phase 2a clinical trial in collaboration with Massachusetts General Hospital for the treatment of abdominal pain and visceral tenderness in patients suffering from irritable bowel syndrome. Each of the studies is utilising TRP-8802 (synthetic, oral psilocybin) to demonstrate clinical benefit in these indications. Where a positive clinical response is demonstrated, subsequent studies are expected to utilise TRP-8803 (IV-infused psilocin), that has the potential to further improve efficacy, safety, and patient experience.

For more information, please visit [www.trypterapeutics.com](http://www.trypterapeutics.com).

### **Investor & Media Contact**

Jason Carroll  
Chief Executive Officer  
Tryptamine Therapeutics Limited  
[jcarroll@trypterapeutics.com](mailto:jcarroll@trypterapeutics.com)

Henry Jordan  
Six Degrees Investor Relations  
+61 (0) 431 271 538  
[henry.jordan@sdir.com.au](mailto:henry.jordan@sdir.com.au)

#### Risks associated with Psilocin

*All medicines carry risks and specialist prescribers, such as registered psychiatrists are best placed to assess the suitability of a new medication against a patient's individual circumstances and medical history before proceeding. Adverse effects of psilocybin and similar compounds, such as psilocin, can include temporary increase in blood pressure and a raised heart rate. There may be some risk of psychosis in predisposed individuals. These effects of psilocybin and its derivatives are unlikely at low doses and in the treatment regimens used in psychedelic-assisted psychotherapy and appropriately managed in a controlled environment with direct medical supervision.*

#### Forward-Looking Information

*Certain information in this news release, constitutes forward looking information. In some cases, but not necessarily in all cases, forward-looking information can be identified by the use of forward-looking terminology such as "plans", "targets", "expects" or "does not expect", "is expected", "an opportunity exists", "is positioned", "estimates", "intends", "assumes", "anticipates" or "does not anticipate" or "believes", or variations of such words and phrases or state that certain actions, events or results "may", "could", "would", "might", "will" or "will be taken", "occur" or "be achieved". In addition, any statements that refer to expectations, projections or other characterizations of future events or circumstances contain forward-looking information. Statements containing forward-looking information are not historical facts but instead represent management's expectations, estimates and projections regarding future events. Forward-looking information is necessarily based on a number of opinions, assumptions and estimates that, while considered reasonable by Tryp as of the date of this news release, are subject to known and unknown risks, uncertainties, assumptions and other factors that may cause the actual results, level of activity, performance or achievements to be materially different from those expressed or implied by such forward looking information, including but not limited to the factors described in greater detail in the "Risk Factors" section of Tryp's Replacement Prospectus available at [www.asx.com.au](http://www.asx.com.au) These factors are not intended to represent a complete list of the factors that could affect Tryp; however, these factors should be considered carefully. There can be no assurance that such estimates and assumptions will prove to be correct. The forward-looking statements contained in this news release are made as of the date of this news release, and Tryp expressly disclaims any obligation to update or alter statements containing any forward-looking information, or the factors or assumptions underlying them, whether as a result of new information, future events or otherwise, except as required by law.*

# Disclosure of Proxy Votes

## Tryptamine Therapeutics Limited

Annual General Meeting

Friday, 08 November 2024



Automic

GPO Box 5193, Sydney, NSW 2001

P 1300 288 664 (aus) or +61 (0)2 9698 5414 (world)

F +61 (0)2 8583 3040 E [hello@automic.com.au](mailto:hello@automic.com.au)

ABN 27 152 260 814

In accordance with section 251AA of the Corporations Act 2001, the following information is provided in relation to resolutions put to members at the meeting.

Resolution	Decided by Show of Hands (S) or Poll (P)	Total Number of Proxy Votes exercisable by proxies validly appointed	Proxy Votes				Poll Results (if applicable)			Results
			FOR	AGAINST	ABSTAIN	PROXY'S DISCRETION	FOR	AGAINST	ABSTAIN	OUTCOME
1 Adoption of Remuneration Report	P	113,692,135	110,834,752 97.49%	2,804,983 2.47%	0	52,400 0.05%	112,609,412 97.57%	2,804,983 2.43%	0	-
2 Re-election of Mr Mark Davies as Director	P	159,411,053	156,747,164 98.33%	2,611,489 1.64%	0	52,400 0.03%	159,029,824 98.38%	2,611,489 1.62%	0	Passed
3 Re-election of Mr Clarke Barlow as Director	P	159,411,053	156,740,564 98.32%	2,618,089 1.64%	0	52,400 0.03%	158,515,224 98.38%	2,618,089 1.62%	508,000	Passed
4 Election of Mr Jason Carroll as Director	P	159,406,253	156,751,975 98.33%	2,601,878 1.63%	4,800	52,400 0.03%	159,034,635 98.39%	2,601,878 1.61%	4,800	Passed
5 Election of Mr Peter Molloy as Director	P	159,406,253	72,547,251 45.51%	86,806,602 54.46%	4,800	52,400 0.03%	74,103,161 46.05%	86,806,602 53.95%	731,550	Not Passed
6 Election of Mr Gage Jull as Director	P	159,406,253	133,745,451 83.90%	25,608,402 16.06%	4,800	52,400 0.03%	136,028,111 84.16%	25,608,402 15.84%	4,800	Passed
7 Election of Mr Christopher Ntoumenopoulos as Director	P	154,406,253	151,751,975 98.28%	2,601,878 1.69%	5,004,800	52,400 0.03%	154,034,635 98.34%	2,601,878 1.66%	5,004,800	Passed
8 ASX Listing Rule 7.1A Approval of Future Issue of Securities	P	159,406,253	154,180,404 96.72%	107,849 0.07%	4,800	5,118,000 3.21%	161,528,664 99.93%	107,849 0.07%	4,800	Passed

For personal use only



For personal use only

Resolution	Decided by Show of Hands (S) or Poll (P)	Total Number of Proxy Votes exercisable by proxies validly appointed	Proxy Votes				Poll Results (if applicable)			Results
			FOR	AGAINST	ABSTAIN	PROXY'S DISCRETION	FOR	AGAINST	ABSTAIN	OUTCOME
9 Approval of Issue of Director Options to Mr Mark Davies, Director and Chair of the Company	P	157,411,053	137,453,270 87.32%	2,839,783 1.80%	2,000,000	17,118,000 10.87%	156,801,530 98.22%	2,839,783 1.78%	2,000,000	Passed
10 Approval of Issue of Director Options to Mr Jason Carroll, Director and CEO of the Company	P	122,111,053	102,153,270 83.66%	2,839,783 2.33%	37,300,000	17,118,000 14.02%	121,501,530 97.72%	2,839,783 2.28%	37,300,000	Passed
11 Approval of Issue of Director Options to Mr Clarke Barlow, Director of the Company	P	159,411,053	139,453,270 87.48%	2,839,783 1.78%	0	17,118,000 10.74%	158,293,530 98.24%	2,839,783 1.76%	508,000	Passed
12 Approval of Issue of Director Options to Mr Christopher Ntoumenopoulos, Director of the Company	P	154,411,053	134,453,270 87.07%	2,839,783 1.84%	5,000,000	17,118,000 11.09%	153,801,530 98.19%	2,839,783 1.81%	5,000,000	Passed
13 Approval of Issue of Director Options to Mr Gage Jull, Director of the Company	P	157,992,135	115,034,352 72.81%	25,839,783 16.36%	0	17,118,000 10.83%	134,382,612 83.87%	25,839,783 16.13%	0	Passed
14 Approval of Issue of Director Options to Mr Peter Molloy, Director of the Company	P	159,411,053	55,253,270 34.66%	87,039,783 54.60%	0	17,118,000 10.74%	73,874,780 45.70%	87,766,533 54.30%	0	Not Passed

